Plaintiffs Suing Jazz in Xyrem Antitrust Row Get Class Certified

The plaintiffs suing Jazz Pharmaceuticals PLC, Hikma Pharmaceuticals PLC, and other drug makers over an alleged scheme to delay generic versions of narcolepsy drug Xyrem convinced a federal court in California to certify their classes, ensuring that the antitrust case will proceed.

Judge Richard Seeborg of the US District Court for the Northern District of California, who certified the plaintiff classes on May 12, also granted preliminary approval of Amneal Pharmaceuticals LLC and Lupin Ltd.'s $3.4 million settlement to exit the case.

The certified classes for plaintiffs seeking damages and injunctive relief include insurers and beneficiaries who paid for or ...